These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16192651)

  • 1. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.
    Jokiranta TS; Cheng ZZ; Seeberger H; Jòzsi M; Heinen S; Noris M; Remuzzi G; Ormsby R; Gordon DL; Meri S; Hellwage J; Zipfel PF
    Am J Pathol; 2005 Oct; 167(4):1173-81. PubMed ID: 16192651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H.
    Cheng ZZ; Hellwage J; Seeberger H; Zipfel PF; Meri S; Jokiranta TS
    Mol Immunol; 2006 Mar; 43(7):972-9. PubMed ID: 16023208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
    Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
    J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells.
    Heinen S; Józsi M; Hartmann A; Noris M; Remuzzi G; Skerka C; Zipfel PF
    J Am Soc Nephrol; 2007 Feb; 18(2):506-14. PubMed ID: 17229916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
    Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
    J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.
    Józsi M; Heinen S; Hartmann A; Ostrowicz CW; Hälbich S; Richter H; Kunert A; Licht C; Saunders RE; Perkins SJ; Zipfel PF; Skerka C
    J Am Soc Nephrol; 2006 Jan; 17(1):170-7. PubMed ID: 16338962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
    Hyvärinen S; Meri S; Jokiranta TS
    Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d.
    Bhattacharjee A; Lehtinen MJ; Kajander T; Goldman A; Jokiranta TS
    Mol Immunol; 2010 May; 47(9):1686-91. PubMed ID: 20378178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of electrostatics on factor H function and related pathologies.
    Kieslich CA; Vazquez H; Goodman GN; López de Victoria A; Morikis D
    J Mol Graph Model; 2011 Aug; 29(8):1047-55. PubMed ID: 21605993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.
    Loeven MA; Rops AL; Lehtinen MJ; van Kuppevelt TH; Daha MR; Smith RJ; Bakker M; Berden JH; Rabelink TJ; Jokiranta TS; van der Vlag J
    J Biol Chem; 2016 Mar; 291(10):4974-81. PubMed ID: 26728463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement.
    Kajander T; Lehtinen MJ; Hyvärinen S; Bhattacharjee A; Leung E; Isenman DE; Meri S; Goldman A; Jokiranta TS
    Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2897-902. PubMed ID: 21285368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H.
    Morgan HP; Jiang J; Herbert AP; Kavanagh D; Uhrin D; Barlow PN; Hannan JP
    Acta Crystallogr D Biol Crystallogr; 2011 Jul; 67(Pt 7):593-600. PubMed ID: 21697597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analyses of the interaction of Borrelia hermsii FhbA with the complement regulatory proteins factor H and factor H-like protein 1.
    Hovis KM; Jones JP; Sadlon T; Raval G; Gordon DL; Marconi RT
    Infect Immun; 2006 Apr; 74(4):2007-14. PubMed ID: 16552029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
    Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
    Front Immunol; 2021; 12():676662. PubMed ID: 34489931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.
    Hebecker M; Alba-Domínguez M; Roumenina LT; Reuter S; Hyvärinen S; Dragon-Durey MA; Jokiranta TS; Sánchez-Corral P; Józsi M
    J Immunol; 2013 Jul; 191(2):912-21. PubMed ID: 23772024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion.
    Amdahl H; Jongerius I; Meri T; Pasanen T; Hyvärinen S; Haapasalo K; van Strijp JA; Rooijakkers SH; Jokiranta TS
    J Immunol; 2013 Aug; 191(4):1775-84. PubMed ID: 23863906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Each of the three binding sites on complement factor H interacts with a distinct site on C3b.
    Jokiranta TS; Hellwage J; Koistinen V; Zipfel PF; Meri S
    J Biol Chem; 2000 Sep; 275(36):27657-62. PubMed ID: 10837479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations.
    Saunders RE; Goodship TH; Zipfel PF; Perkins SJ
    Hum Mutat; 2006 Jan; 27(1):21-30. PubMed ID: 16281287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
    Kopp A; Strobel S; Tortajada A; Rodríguez de Córdoba S; Sánchez-Corral P; Prohászka Z; López-Trascasa M; Józsi M
    J Immunol; 2012 Aug; 189(4):1858-67. PubMed ID: 22786770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.